603259 WuXi AppTec
- 45.57
- -0.21-0.46%
WuXi AppTec News
Wuxi Pharmaceutical Kangde New Drug Development Co., Ltd. 2024 H Share Incentive Trust Plan (Draft)
Notice on changing the registered capital of the company and amending the company's articles of association
Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Notice on amending the company's articles of association
Announcement on the launch of foreign exchange hedging business
2023 Internal Control Evaluation Report
Notice on Using Idle Own Funds for Cash Management
2023 Annual Report of the Board of Directors Audit Committee
Announcement on the shareholding status of the top ten shareholders and the top ten shareholders with unlimited sales conditions in the matter of repurchasing A-shares
Further announcements on clarifications
Announcement on the shareholding status of the top ten shareholders and the top ten shareholders with unlimited sales conditions in the matter of repurchasing A-shares
Further announcements on clarifications
Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders, the 2024 First Class A Shareholders\' Meeting, and the 2024 First Class H Shareholders\' Meeting
Legal Opinions of Shanghai Fangda Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Wuxi Yakming Kangde New Pharmaceutical Development Co., Ltd., the first Class A Shareholders\' Meeting in 2024, and the First Class H Shareholders
Notice on holding the 2024 First Extraordinary General Meeting of Shareholders, the 2024 First Class A Shareholders Meeting, and the 2024 First H Share Class Shareholders\' Meeting
Meeting materials for the 2024 First Extraordinary General Meeting of Shareholders, 2024 First Class A Shareholders Meeting, and 2024 First H Share Class Shareholders\' Meeting
Announcement on the listing of the participating company WuXi XDC Cayman Inc., on the main board of the Hong Kong Stock Exchange
Announcement on subscribing to private equity fund shares
Voluntary announcement on the production capacity expansion project of the peptide production workshop of Hequan Pharmaceutical, a subsidiary of Wuxi Yaoming Kangde New Drug Development Co., Ltd.
Legal opinions of Shanghai Fangda Law Firm on the 2022 Annual General Meeting of Shareholders of Wuxi Yaoming Kangde Pharmaceutical Development Co., Ltd., the first A-share shareholders\' meeting in 2023, and the first H-share shareholders\' meeting in 202
Analysis
Price Target
No Data
